Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

September 26, 2025

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; and Tiffany A. Traina, MD, FASCO; discuss navigating between currently available therapies for patients with triple-negative breast cancer (TNBC). They also discuss the potential ramifications of ongoing clinical trials on future treatment paradigms.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Develop evidence-based strategies for integrating antibody-drug conjugates (ADCs) in the management of patients with metastatic TNBC
Apply effective methods to mitigate adverse effects associated with ADCs in patients with metastatic TNBC

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Faculty:

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine, Geffen School of Medicine
University of California, Los Angeles
Program Director, Breast Medical Oncology
Assistant Chief of Translational Research, Division of Hematology-Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, CA

Disclosures: Consultant: Alyssum, Daiichi Sankyo/AstraZeneca, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer; Research (paid to institution): Alyssum, Daiichi Sankyo/AstraZeneca, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer.

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Chair, Breast Executive Committee
Sarah Cannon Research Institute
Nashville, TN

Disclosures: Consultant (all payments to institution): Accutar Biotechnology, Arvinas, AstraZeneca, BeiGene, Circle Pharma, Daiichi Sankyo, Entos, Gilead Sciences, Halda Therapeutics, Incyclix Bio, IQVIA, Janssen, Jazz Pharmaceuticals, Jefferies LLC, Johnson & Johnson, Lilly, Medical Pharma Services, Mersana, Novartis, Pfizer, Pyxis Oncology, Roche/Genentech, Samsung Bioepis, Shorla Pharma, Stemline Therapeutics, Tempus Labs, Zentalis Pharmaceuticals; Research Funding (all payments to institution): AbbVie, Accutar Biotechnology, Acerta Pharma, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss BioPharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Cascadian Therapeutics, Clovis, Compugen, Context Therapeutics, Cullinan, Curis, CytomX, Daiichi Sankyo, Dana-Farber Cancer Institute, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Eisai, Ellipses Pharma, Elucida Oncology, EMD Serono, Fochon Pharmaceuticals, FujiFilm, G1 Therapeutics, Gilead Sciences, H3 Biomedicine, Harpoon, Hutchison MediPharma, Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals, Inspirna, InventisBio, Jacobio, Karyopharm, K-Group Beta, Kind Pharmaceuticals, Leap Therapeutics, Lilly, Loxo Oncology, Lycera, MabSpace Biosciences, MacroGenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Myriad Genetic Laboratories, Novartis, NuCana, Olema, OncoMed, Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum Therapeutics, Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Plexxikon, Prelude Therapeutics, Profound Bio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, Seagen, Sermonix Pharmaceuticals, Shattuck Labs, Silverback Therapeutics, Stemcentrx, Stemline Therapeutics, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque Therapeutics, Treadwell Therapeutics, Verastem, Zenith Epigenetics, Zymeworks.

Tiffany A. Traina, MD, FASCO

Associate Professor of Medicine
Weill Cornell Medicine
Associate Attending Physician
Vice Chair, Oncology
Department of Medicine
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: Astellas Pharma, AstraZeneca, Ayala Pharmaceuticals, Daiichi Sankyo, Genentech/Roche, Pfizer; Consultant: AstraZeneca, Biotheranostics, Daiichi Sankyo, Exact Sciences, G1 Therapeutics, Genentech/Roche, Gilead Sciences, GSK, Hengrui Pharmaceuticals, Merck, Novartis, Pfizer, Stemline Therapeutics, TerSera.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on integrating TROP2-targeting strategies into routine clinical practice, go to https://www.gotoper.com/courses/expert-roundtable-and-panel-discussions-current-and-future-landscape-of-tnbc.

Release Date

September 26, 2025

Expiration Date

September 26, 2026

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.